Equities

Rhythm Biosciences Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert

Rhythm Biosciences Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (AUD)0.21
  • Today's Change0.005 / 2.44%
  • Shares traded1.45m
  • 1 Year change+133.33%
  • Beta0.9288
Data delayed at least 20 minutes, as of Feb 17 2026 05:10 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Rhythm Biosciences Ltd is an Australia-based medical diagnostics company. The Company is engaged in delivering simple, affordable blood tests for accurate and early detection of cancers. It is focused on improving patient outcomes through detection at the earliest possible stage, reducing the global burden of cancer and saving lives. The Company’s blood-based technology, a blood test for the detection of Colorectal Cancer (CRC). The ColoSTAT Test-Kit measures five specific protein biomarkers that indicate the likelihood of CRC. The test is an alternative for individuals who are unable or unwilling to participate in current screening programs. It is being updated to meet the IVDR (In vitro diagnostic medical devices regulation) regulatory standards. Its geneType platform personalized predictive test portfolio that uses a combination of genomic and clinical information to predict risk of chronic disease development.

  • Revenue in AUD (TTM)3.33m
  • Net income in AUD-3.83m
  • Incorporated2017
  • Employees--
  • Location
    Rhythm Biosciences LtdBio21 Institute30 Flemington Road, ParkvilleMELBOURNE 3010AustraliaAUS
  • Phone+61 39614-0600
  • Fax+61 39614-0550
  • Websitehttps://www.rhythmbio.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Algorae Pharmaceuticals Ltd141.05k-802.96k33.78m----15.14--239.46-0.0005-0.00050.000080.00130.0505--3.38---28.72-51.95-30.63-56.76-----569.27-1,452.78----0.00--12.66-23.9361.68------
Neuroscientific Biopharmaceuticals Ltd166.08k-1.85m39.91m----2.37--240.30-0.0126-0.01260.00110.05060.0148--2.17---16.48-37.13-16.65-40.11-----1,111.22-185.57---746.170.00---93.0516.84-669.23------
Anteotech Ltd1.03m-6.76m41.62m40.00--12.02--40.50-0.0025-0.00250.00040.00120.1299--6.90---85.41-76.84-106.22-87.65-----657.69-1,253.69----0.3835--99.6027.9723.89---4.02--
Emyria Ltd1.39m-3.14m45.97m----6.57--32.96-0.0069-0.00690.00310.00870.2316--40.72---52.19-82.51-69.83-106.691.76-17.98-225.33-355.61---22.440.1037---36.686.6072.57---41.45--
Syntara Ltd7.48m-12.26m52.26m107.00--3.25--6.99-0.0084-0.00540.00510.00990.4701--2.53---77.03-36.39-116.54-50.26-----163.86-78.37---953.380.0052--37.80-9.8310.31------
Entropy Neurodynamics Ltd1.59m-5.33m56.31m----8.69--35.47-0.0043-0.00430.00120.00410.2249--0.763---75.55---92.06-------335.91-----100.790.00-----10.25-----26.73--
Amplia Therapeutics Ltd5.01m-7.93m61.57m1.00--1.43--12.30-0.0204-0.02040.01280.08370.1705--1.28---27.01-27.37-28.31-30.38-----158.46-180.53----0.0088---15.01156.11-45.93------
Clever Culture Systems Ltd6.52m1.68m63.14m17.0037.189.0833.079.680.00080.00080.00310.00320.69750.98296.37--18.01-36.7322.73-42.0077.05--25.82-281.211.63--0.2653--397.8630.08145.03--24.71--
Proteomics International LaboratoriesLtd3.31m-8.11m66.07m----4.97--19.95-0.0605-0.06050.02470.08050.2582--12.02---63.57-63.62-68.88-71.91-----246.18-222.10----0.021--1.3415.81-27.27---54.88--
Rhythm Biosciences Ltd3.33m-3.83m67.05m----90.19--20.16-0.0134-0.01340.01240.00231.5398.7967.11---176.04-146.24-469.96-197.40-10.4422.48-115.14-287.420.8046-53.890.6266--90.87135.1444.15---12.61--
Prescient Therapeutics Ltd225.61k-7.32m67.30m3.00--4.53--298.29-0.0091-0.00910.00030.01410.0129--0.9582---41.90-31.70-49.69-34.33-----3,245.66-2,146.75---590.480.00---67.1926.2411.11------
Imugene Ltd0.00-69.02m81.99m0.00--1.24-----0.3161-0.31610.000.2050.00-------58.75-48.72-75.21-53.73------------0.1913------53.89--38.40--
Cynata Therapeutics Ltd227.70k-9.39m87.86m0.00--13.98--385.85-0.0453-0.04530.00110.02650.0292--2.16---120.50-48.36-142.29-53.09-----4,124.10-576.20---1,268.000.00---45.4928.123.63------
Alterity Therapeutics Ltd446.29k-12.15m92.44m9.00--1.83--207.13-0.002-0.0020.000070.00470.0137--5,578.6349,587.78-37.23-49.00-43.12-57.35-----2,721.96-9,708.51---211.820.0037--66.2791.9736.48------
LTR Pharma Ltd2.10m-5.59m94.52m----2.99--44.93-0.0333-0.03330.01260.17410.1183--8.22---31.44---32.47-------265.90--45.76-62.540.00--4,164.38--19.57------
Tetratherix Ltd1.14m-9.43m98.38m----6.69--86.10-0.1873-0.18730.02270.54140.0688--2.22---56.71---76.72---172.06---824.89-----98.750.0697--32.30---269.05------
Data as of Feb 17 2026. Currency figures normalised to Rhythm Biosciences Ltd's reporting currency: Australian Dollar AUD

Institutional shareholders

7.80%Per cent of shares held by top holders
HolderShares% Held
FIL Investment Management (Hong Kong) Ltd.as of 31 Dec 202519.80m5.87%
FIL Pensions Managementas of 30 Jun 20256.51m1.93%
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.